I am a hematologist and attended a review course sponsored by Dana Farber Cancer institute this past Saturday. Jakafi(Incyte) has become a huge success for treating myelofibrosis; however, it exacerbates the low platelet count which frequently accompanies myelofibrosis. The studies to date suggest that Pacritinib is equally efficacious WITHOUT causing a reduction in platelets. I see great potential for pacritinib to displace Jakafi. Jakafi has propelled INCY to a market cap of 5 billion!